

Influenza Work Group

Introduction

Ruth Karron, MD

Advisory Committee on Immunization
Practices

June 22, 2016

Recent WG Discussion

- ❑ Update on vaccine safety for 2015-16.
- ❑ Presentations on Flulaval Quadrivalent and Flucelvax Quadrivalent.
- ❑ Discussion of vaccine effectiveness data for 2015-16, including effectiveness of LAIV and IIV, from the US Influenza Vaccine Effectiveness (US Flu VE) Network and MedImmune

Influenza Work Group

ACIP Members

Ruth Karron (Chair)
Ed Belongia
Lee Harrison
Emmanuel (Chip) Walter

***Ex Officio* Members**

Karin Bok (HHS)
David Cho (FDA)
Bruce Gellin (HHS)
Lucia Lee (FDA)
Cynthia Noletti (FDA)
Roshan Ramanathan (FDA)
Rachelle Salomon (NIH)
David Spiro (NIH)

Consultants

Jeff Duchin
Wendy Keitel

Liaison Representatives

Kevin Ault (ACOG)
Hank Bernstein (AAP)
Jan Englund (PIDS)
Sandra Fryhofer (ACP; AMA)
Marie-Michèle Léger (AAPA)
Susan Lett (CSTE)
Jamie Loehr (AAFP)
Flor Munoz (AAP)
Kathy Neuzil (IDSA)
William Schaffner (NFID)
Rob Schechter (AIM)
Ken Schmader (AGS)
Patsy Stinchfield (NAPNAP)
Tamara Sheffield (AHIP)
Wendy Vaudry (NACI)
Matthew Zahn (NACCHO)

CDC Lead

Lisa Grohskopf (CDC/NCIRD, Influenza Division)

Agenda Overview

- ❑ **Flulaval Quadrivalent**
 - Dr. Bruce Innis (GlaxoSmithKline)

- ❑ **Flucelvax Quadrivalent**
 - Dr. James Mansi (Seqirus)

- ❑ **Vaccine Safety Update**
 - Dr. Tom Shimabukuro (CDC/NCEZID)

- ❑ **Vaccine Effectiveness**
 - Dr. Chris Ambrose (MedImmune)
 - Dr. Brendan Flannery (CDC/NCIRD)

- ❑ **Proposed recommendations**
 - Dr. Lisa Grohskopf (CDC—Influenza Division)